Related Experiment Video
Updated: Apr 15, 2026
09:04
In Vitro ELISA Test to Evaluate Rabies Vaccine Potency
Published on: May 11, 2020
13.5K
A Bivalent, Chimeric Rabies Virus Expressing Simian Immunodeficiency Virus Envelope Induces Multifunctional Antibody
Amber Dunkel1, Shixue Shen1, Celia C LaBranche2
11 Department of Microbiology and Immunology, Thomas Jefferson University , Philadelphia, Pennsylvania.
AIDS Research and Human Retroviruses
|April 8, 2015
Summary
A novel rabies virus-based vaccine (RABV-ΔM-Env) expressing SIV proteins induced potent B cell responses in mice. Intradermal inoculation enhanced antibody quality and effector functions, suggesting potential for HIV-1 vaccine development.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- Rabies virus-based vaccine (RABV-ΔM) is immunogenic and elicits strong B cell responses.
- RABV-ΔM expressing HIV proteins may induce potent B cell responses against HIV antigens.
Purpose of the Study:
- To assess the immunogenicity of RABV-ΔM expressing SIVmac239Env (RABV-ΔM-Env) in mice.
- To confirm RABV-ΔM's ability to induce polyfunctional B cell responses against HIV antigens.
Main Methods:
- Cloned SIVmac239Env into RABV-ΔM, creating RABV-ΔM-Env.
- Confirmed Env expression via Western blot.
- Administered RABV-ΔM-Env via intramuscular inoculation in mice and assessed neutralization activity.
Main Results:
- Single intramuscular inoculation induced neutralization activity against SIV strains.
- Boosting enhanced antibody avidity and Th1-type response.
- Intradermal inoculation yielded higher antibody levels than intramuscular or intranasal routes.
- Intradermal inoculation followed by gp130 boost produced anti-SIV antibodies with neutralizing and non-neutralizing functions.
Conclusions:
- RABV-ΔM-Env induces B cells to secrete antibodies against SIV with potential to clear both free and cell-associated virus.
- Strategies eliciting both neutralizing and non-neutralizing antibodies may improve HIV-1 vaccine efficacy.
